Athersys

OverviewSuggest Edit

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases.  The Company is engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of the proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

TypePublic
Founded1995
HQCleveland, OH, USMap
Websiteathersys.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)83(+11%)
Revenue (FY, 2019)$5.6 M(-76%)
Share Price (Jan 2021)$1.9 (+7%)
Cybersecurity ratingAMore

Key People/Management at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Founder, Chairman & CEO
Manal Morsy

Manal Morsy

Senior Vice President and Head of Global Regulatory Affairs
Ivor MacLeod

Ivor MacLeod

Chief Financial Officer
John Harrington

John Harrington

Executive Vice President, Chief Scientific Officer & Director
William Lehmann

William Lehmann

President and Chief Operating Officer
Ismail Kola

Ismail Kola

Lead Director
Show more

Athersys Office Locations

Athersys has offices in Cleveland and Canton
Cleveland, OH, US (HQ)
3201 Carnegie Ave
Canton, MA, US
250 Royall St
Show all (2)

Athersys Financials and Metrics

Athersys Revenue

Athersys's revenue was reported to be $5.63 m in FY, 2019
USD

Revenue (Q2, 2020)

77.0k

Market capitalization (22-Jan-2021)

383.5m

Closing stock price (22-Jan-2021)

1.9

Cash (30-Jun-2020)

80.7m
Athersys's current market capitalization is $383.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.3m8.7m2.4m1.6m11.9m17.3m3.7m24.3m5.6m

Revenue growth, %

(33%)636%45%

General and administrative expense

4.9m4.8m6.1m6.9m7.5m7.8m8.5m10.4m11.4m

R&D expense

18.9m19.6m20.5m23.4m21.3m24.8m27.8m38.7m39.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.4m2.4m2.7m2.7m1.0m326.0k571.0k621.0k707.0k388.0k293.0k731.0k216.0k396.0k15.5m595.0k311.0k1.5m669.0k399.0k1.1m19.4m2.3m1.4m4.3m(361.0k)77.0k

General and administrative expense

1.4m1.1m1.3m1.2m1.1m1.5m1.6m1.5m1.8m1.8m1.7m1.9m1.9m1.9m2.0m2.0m1.8m2.1m2.2m2.1m2.7m2.4m2.6m3.1m2.9m3.0m3.5m

R&D expense

4.4m4.3m5.6m5.0m4.1m5.6m5.1m4.7m6.2m5.8m5.8m5.7m5.3m5.1m6.7m5.8m5.3m5.6m4.6m5.4m8.9m10.1m9.5m11.4m11.1m8.9m12.1m

Operating expense total

5.8m5.4m6.8m6.2m5.2m7.1m6.7m6.1m8.0m7.6m7.5m7.6m7.2m7.0m8.7m7.8m7.1m7.7m6.8m7.6m11.5m12.5m12.1m14.5m14.0m11.8m15.6m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

8.8m25.5m31.9m26.1m23.0m14.8m29.3m51.1m35.0m

Accounts Receivable

689.0k490.0k520.0k694.0k361.0k598.0k739.0k262.0k

Prepaid Expenses

304.0k286.0k387.0k427.0k429.0k1.1m1.8m1.2m

Current Assets

14.4m26.3m32.9m27.2m23.8m16.3m31.2m57.8m37.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

4.7m8.5m14.8m10.9m7.9m21.3m18.9m17.8m45.0m38.8m32.4m35.5m32.3m28.5m30.4m13.8m8.3m31.9m28.6m28.2m49.7m53.4m48.0m51.0m44.2m40.4m32.7m80.7m

Accounts Receivable

426.0k177.0k399.0k704.0k438.0k473.0k576.0k453.0k894.0k715.0k665.0k2.8m2.4m315.0k706.0k648.0k298.0k1.8m608.0k707.0k759.0k545.0k573.0k

Prepaid Expenses

341.0k636.0k256.0k305.0k370.0k293.0k328.0k283.0k319.0k310.0k416.0k386.0k341.0k383.0k426.0k999.0k855.0k1.2m920.0k1.0m1.0m2.5m2.2m800.0k849.0k614.0k1.5m1.1m

Current Assets

21.9m17.5m17.0m12.0m8.7m22.1m19.8m18.6m46.2m39.8m33.4m38.7m35.1m29.2m31.5m25.7m20.5m34.9m30.1m30.0m58.4m69.5m62.6m54.3m48.1m42.5m34.5m81.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(13.7m)(14.7m)(30.7m)(22.1m)(16.4m)(15.3m)(32.2m)(24.3m)(44.6m)

Depreciation and Amortization

278.0k320.0k346.0k360.0k267.0k382.0k684.0k855.0k698.0k

Accounts Payable

983.0k201.0k(196.0k)335.0k(296.0k)2.4m1.5m4.3m

Cash From Operating Activities

(14.5m)(17.7m)(22.8m)(25.8m)(13.8m)(10.9m)(24.0m)(13.3m)(35.3m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(7.2m)(9.5m)(4.3m)(8.0m)(11.5m)(9.4m)(15.3m)(20.9m)(11.5m)(10.8m)(15.5m)(12.5m)(13.5m)(20.0m)4.8m(2.2m)(8.2m)(5.6m)(11.9m)(19.1m)(10.2m)(3.2m)(13.0m)(13.0m)(22.6m)(34.7m)(15.6m)(34.0m)

Depreciation and Amortization

127.0k202.0k75.0k155.0k236.0k85.0k171.0k257.0k89.0k182.0k272.0k70.0k136.0k201.0k68.0k134.0k248.0k164.0k331.0k508.0k186.0k376.0k573.0k184.0k341.0k508.0k190.0k412.0k

Accounts Payable

897.0k919.0k(233.0k)(132.0k)(724.0k)501.0k30.0k(890.0k)(239.0k)11.0k295.0k(678.0k)(769.0k)(529.0k)400.0k900.0k765.0k1.0m(670.0k)(1.0m)2.0m6.3m5.3m1.2m1.2m1.7m3.7m

Cash From Operating Activities

(5.8m)(10.0m)(5.4m)(10.4m)(14.0m)(6.1m)(12.5m)(18.3m)(7.3m)(13.4m)(19.7m)1.1m(4.7m)(8.4m)7.3m852.0k(4.6m)(5.4m)(11.1m)(17.9m)(5.7m)(1.3m)(8.8m)(5.5m)(17.0m)(25.2m)(12.1m)(24.8m)
show all
USDQ2, 2011

Financial Leverage

1.8 x
Show all financial metrics

Athersys Operating Metrics

FY, 2016

Patent Applications

170

Patents (US)

21

Patents Issued

200
Show all operating metrics

Athersys Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Athersys Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Athersys Online and Social Media Presence

Athersys's Trends

Embed Graph

Athersys News and Updates

September 23, 2020

Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, PRTY, ACRX, LUV, and CCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
September 23, 2020

Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, PRTY, ACRX, LUV, and CCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
August 24, 2020

Translational Regenerative Medicines Market is growing at a CAGR of 13.9% by 2026 | Athersys, Orthofix International N.V, Anika Therapeutics

The latest 184+ page survey report on Translational Regenerative Medicines - Global Market is released by HTF MI covering various players of the industry selected from global geographies like North America, Europe, Asia Pacific, South America & Middle East & Africa. A perfect mix of quantita…
June 22, 2020

Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?

NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
March 30, 2020

HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares

Athersys, Inc. (“Athersys”) (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (“Healios”), exercised in full its warrant to purchase shares of Athersys common stock. Healios purchased 4,000,000 shares at a price of $1.76 per share in accordance with the terms of the warrant, rep…
January 15, 2020

Athersys Names Ivor Macleod Chief Financial Officer

Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercial…
Show more

Athersys Blogs

February 14, 2019

Athersys Year End 2018 Results Webcast

Athersys Year End 2018 Results Webcast joseibrahim.de… Thu, 02/14/2019 - 09:35 Athersys Year End 2018 Results Webcast Display "add to calendar" true Event Type Earnings Conference Call Event Categories …
February 14, 2019

Athersys to Host Year-End 2018 Financial Results Call

Athersys to Host Year-End 2018 Financial Results Call Content Import Thu, 02/14/2019 - 08:06 Athersys to Host Year-End 2018 Financial Results Call February 14, 2019 at 8:00 AM EST This release is a backfill from a News Wire General CL…
January 07, 2019

JP Morgan Healthcare Conference

JP Morgan Healthcare Conference khunady@athersys.com Mon, 01/07/2019 - 09:04 JP Morgan Healthcare Conference Display "add to calendar" true Event Type Other Corporate Event Categories Default Calendar …
December 17, 2018

Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China

Parties working together on development plan in China CLEVELAND, Ohio , Dec. 17, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development
December 04, 2018

ISCT Webinar – Partnering in Japan: The Athersys - Healios Story

ISCT Webinar – Partnering in Japan: The Athersys - Healios Story joseibrahim.de… Tue, 12/04/2018 - 16:29 ISCT Webinar – Partnering in Japan: The Athersys - Healios Story Display "add to calendar" true Event Type Other Corporate …
October 11, 2018

2018-10-11 Cleveland Clinic Medical Innovation Summit

2018-10-11 Cleveland Clinic Medical Innovation Summit khunady@athersys.com Thu, 10/11/2018 - 17:05 Cleveland Clinic Medical Innovation Summit Display "add to calendar" true Event Type Conference Event Categories …
Show more

 Athersys Frequently Asked Questions

  • When was Athersys founded?

    Athersys was founded in 1995.

  • Who are Athersys key executives?

    Athersys's key executives are Gil Van Bokkelen, Manal Morsy and Ivor MacLeod.

  • How many employees does Athersys have?

    Athersys has 83 employees.

  • What is Athersys revenue?

    Latest Athersys annual revenue is $5.6 m.

  • What is Athersys revenue per employee?

    Latest Athersys revenue per employee is $67.9 k.

  • Who are Athersys competitors?

    Competitors of Athersys include Seed Health, BeyondSpring and Rani Therapeutics.

  • Where is Athersys headquarters?

    Athersys headquarters is located at 3201 Carnegie Ave, Cleveland.

  • Where are Athersys offices?

    Athersys has offices in Cleveland and Canton.

  • How many offices does Athersys have?

    Athersys has 2 offices.